Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
Aneurysm II: Clinical Manifestations and Diagnostic Studies01:21

Aneurysm II: Clinical Manifestations and Diagnostic Studies

Thoracic, aortic arch and abdominal aneurysms are significant vascular conditions that can present with various clinical manifestations and lead to serious complications. Understanding these manifestations and the appropriate diagnostic studies is essential for effective management and treatment.Thoracic Aortic AneurysmsThoracic aortic aneurysms often remain asymptomatic until they reach a size that impinges on adjacent structures. They typically cause deep, diffuse chest pain that radiates to...
Dysrhythmias I: Introduction01:15

Dysrhythmias I: Introduction

Dysrhythmias refers to abnormalities in the heart's rhythm. They result from disruptions in the heart's electrical conduction system, which includes the sinoatrial(SA)node, atrioventricular(AV) node, the bundle of His, bundle branches, and Purkinje fibers.Definition and PathophysiologyDysrhythmias result from disorders of impulse formation, impulse conduction, or both. The heart contains specialized cells in the sinoatrial node, atrioventricular node, and the bundle of His and Purkinje fibers...
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
Mitral Stenosis I: Introduction01:22

Mitral Stenosis I: Introduction

Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Limitations of current risk stratification in FLNC truncating variant carriers: A family study with multiple sudden cardiac deaths.

Kardiologia polska·2026
Same author

Left Atrial Mechanical Function Following Hybrid Epicardial-Endocardial Versus Endocardial Catheter Ablation: A Randomized Mechanistic Trial.

Heart rhythm·2026
Same author

Unravelling the grey zone: submaximal-to-peak stress echocardiography enhances diagnostic accuracy in differentiating early dilated cardiomyopathy from physiological adaptation.

Echo research and practice·2026
Same author

Dysregulated T Cell-Mediated Immunity Underlies Progression of Arrhythmogenic Right Ventricular Cardiomyopathy.

Circulation·2026
Same author

Convergent Hybrid Ablation Versus Catheter Ablation in Patients With Persistent Atrial Fibrillation and Heart Failure: HALT AF Study Protocol and Rationale for a Multicenter Randomized Controlled Trial.

Journal of the American Heart Association·2026
Same author

Prospective use of genomics in the evaluation of sudden cardiac death: results from a national health service population pathway.

EBioMedicine·2026

Related Experiment Video

Updated: May 13, 2026

Microelectrode Array Recording of Sinoatrial Node Firing Rate to Identify Intrinsic Cardiac Pacemaking Defects in Mice
09:20

Microelectrode Array Recording of Sinoatrial Node Firing Rate to Identify Intrinsic Cardiac Pacemaking Defects in Mice

Published on: July 5, 2021

Brugada syndrome: an update.

Anthony Li1, Elijah R Behr

  • 1Cardiovascular Sciences Research Centre, St George's University of London, Cranmer Terrace, London, SW17 0RE, UK.

Future Cardiology
|March 8, 2013
PubMed
Summary
This summary is machine-generated.

Brugada syndrome, a heart condition, presents a wide risk spectrum, with most patients being low risk. Current management remains challenging due to lack of drug therapy and implantable cardioverter defibrillator complications.

More Related Videos

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation
07:15

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation

Published on: January 16, 2019

Spinal Cord Electrophysiology
04:59

Spinal Cord Electrophysiology

Published on: January 18, 2010

Related Experiment Videos

Last Updated: May 13, 2026

Microelectrode Array Recording of Sinoatrial Node Firing Rate to Identify Intrinsic Cardiac Pacemaking Defects in Mice
09:20

Microelectrode Array Recording of Sinoatrial Node Firing Rate to Identify Intrinsic Cardiac Pacemaking Defects in Mice

Published on: July 5, 2021

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation
07:15

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation

Published on: January 16, 2019

Spinal Cord Electrophysiology
04:59

Spinal Cord Electrophysiology

Published on: January 18, 2010

Area of Science:

  • Cardiology
  • Genetics
  • Electrophysiology

Background:

  • Brugada syndrome is a rare genetic heart condition characterized by abnormal electrocardiogram (ECG) findings and an increased risk of sudden cardiac death.
  • First described over 20 years ago, the syndrome initially presented with coved ST-segment elevation in right precordial leads in patients with no structural heart disease.
  • Subsequent research and registry data revealed a broader clinical spectrum, with the majority of affected individuals classified as low risk.

Purpose of the Study:

  • To review the current understanding and management of Brugada syndrome.
  • To highlight controversies in pathophysiology and risk stratification for sudden cardiac death.
  • To discuss state-of-the-art therapies and their associated challenges.

Main Methods:

  • This review synthesizes information from published literature, including original case series, registry data, and consensus documents.
  • It critically analyzes current research on Brugada syndrome's pathophysiology and risk stratification.
  • The review focuses on evaluating contemporary therapeutic strategies and their complications.

Main Results:

  • Brugada syndrome exhibits a wide range of risk, with most patients being low risk, contrary to initial descriptions.
  • Significant controversies persist regarding the underlying pathophysiology and accurate risk stratification for sudden cardiac death.
  • Current management strategies, including implantable cardioverter defibrillators, are associated with high complication rates and lack of effective drug therapy.

Conclusions:

  • Despite extensive research, Brugada syndrome remains a complex condition with ongoing debates on its mechanisms and risk assessment.
  • Effective pharmacological treatments are lacking, and device-based therapies carry significant risks.
  • Further research is needed to refine risk stratification and develop safer, more effective management strategies for Brugada syndrome.